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H I G H L I G H T S
• Many DAR heteromers have been identified but their biological significance is only emerging.• Targeting DAR heteromers has a strong therapeutic potential the field of addiction.• The selective inhibition of receptor heteromers is a major limitation to uncover their roles in vivo.
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A B S T R A C T
Drug addiction is a chronic and relapsing disorder that leads to compulsive drug intake despite deleterious
consequences. By increasing dopamine (DA) in the mesolimbic system, drugs of abuse hijack the brain reward
circuitry, which is critical for the development of enduring behavioral alterations. DA mainly acts onto DA D1
(D1R) and D2 (D2R) receptor subtypes, which are positively and negatively coupled to adenylyl cyclase, re-
spectively. Extensive research has aimed at targeting these receptors for the treatment of addiction, however this
often results in unwanted side-effects due to the implication of DA receptors in numerous physiological func-
tions. A growing body of evidence indicates that the physical interaction of DA receptors with other receptors
can finely tune their function, making DA receptor heteromers promising targets for more specific treatment
strategies. An increasing number of articles highlighted the ability of both D1R and D2R to form heteromers,
however, most studies carried out to date stem from observations in heterologous systems and the biological
significance of DA receptor heteromers in vivo is only emerging. We focused this review on studies that were able
to provide insights into functions on D1R and D2R heteromers in drug-evoked adaptations and discuss the
limitations of current approaches to study receptor heteromers in vivo.
This article is part of the Special Issue entitled ‘Receptor heteromers and their allosteric receptor-receptor
interactions’.
1. Introduction
Drug addiction is a chronic and relapsing disorder that results from
protracted drug consumption by vulnerable individuals, leading to
compulsive drug intake despite deleterious consequences. Drug-evoked
neuronal activity changes within the so-called brain reward circuit are
fundamental for the instatement of the enduring behavioral alterations
that are characteristic of addiction (Lüscher and Malenka, 2011). Such
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modulations of synaptic efficacy are translated into specific patterns of
signaling pathway activation and gene expression driving a long-lasting
remodeling of neural circuits, likely involved in the transition from
casual to compulsive drug intake and addiction (Nestler, 2001, 2014).
Despite their distinct targets, all drugs of abuse hijack the natural
reward system by increasing dopamine (DA) concentration in the me-
solimbic system, especially in the striatum (Di Chiara and Imperato,
1988), resulting in alterations in glutamate transmission-dependent
plasticity (Lüscher and Malenka, 2011). The striatum is considered a
key target structure of drugs of abuse within the reward circuit because
it is at the crossroad of converging glutamate signals arising from
limbic, thalamic and cortical regions, which encode components of
drug-associated stimuli and environment, along with DA transmission
that mediates reward prediction error and incentive values.
This integration of DA and glutamate inputs is mainly accomplished
by the Medium-sized Spiny GABAergic Neurons (MSN), which receive
glutamate axon terminals and DA afferences converging on MSN den-
dritic spines (Moss and Bolam, 2008; Doig et al., 2010). MSN form
primarily two segregated populations based on the expression of either
DA D1 (D1R) or DA D2 (D2R) receptors, which are G protein-coupled
receptors (GPCR) positively and negatively coupled to adenylyl cyclase
though their respective coupling to Gs/olf and Gi/o subtypes (Felder
et al., 1991; Corvol et al., 2001), although a fraction of MSN in the
ventral striatum (i.e. nucleus accumbens; NAcc) express both receptors
(Bertran-Gonzalez et al., 2008).
These two sub-populations of MSN also display distinct projections
within the cortico-basal ganglia network with the D1R-MSN and D2R-
MSN forming the direct pathway (dMSN) and the indirect pathway
(iMSN), respectively. In the dorsal part of the striatum, dMSN and iMSN
exert opposite functions regarding the control of motor behavior.
Optogenetic stimulations of dorsal dMSN and iMSN has been shown to
promote and inhibit locomotion, respectively (Kravitz et al., 2010).
Within the NAcc, this functional dichotomy also applies to reward-
dependent learning since the activation of the direct pathway neurons
promotes reward whereas the stimulation of indirect pathway neurons
is associated with punishment (Hikida et al., 2010; Lobo et al., 2010;
Kravitz et al., 2012).
The surge of DA induced by drugs of abuse thus triggers a stimu-
lation of D1R that activates dMSN and promotes reiforcement, whereas
the D2R-mediated inhibition iMSN opposes to aversion, explaining why
a high rewarding value of a stimuli is set when both D1R and D2R are
stimulated. Based on these observations, it has been proposed that the
imbalance between the activity of dMSN and iMSN evoked by drugs of
abuse may drive towards compulsive drug intake and addiction (Lobo
and Nestler, 2011; Volkow and Morales, 2015).
We and others have started to identify the underlying cellular and
molecular mechanisms (Girault et al., 2007; Cahill et al., 2014a; Pascoli
et al., 2014a). We found that a single cocaine administration triggers a
D1R-mediated facilitation of N-methyl-D-aspartate glutamate receptors
(NMDAR) that activates in dMSN the extracellular signal-regulated ki-
nase1/2 (ERK1/2), which controls epigenetic and genic responses that
are mandatory for the development of long-term behavioral alterations
(Pascoli et al., 2011a, 2014a,b).
Although the implication of DA and glutamate signaling crosstalk in
drug-evoked neuronal adaptations is well acknowledged, targeting the
cognate receptors to alleviate symptoms is associated with a loss of
efficacy over time and the appearance of severe sides effects, likely due
to the involvement of these receptors in fundamental physiological
Table 1
Modulation and functions of endogenous dopamine receptor heteromers in response to drugs of abuse in vivo.
Psychostimulant-Animal model Dopamine receptor heteromer modulation Impact on drug-evoked responses References
Rat; acute cocaine (30mg/kg i.p) D2R/GluN2B heteromers 30 min post-cocaine in the
NAcc and dStr.
D2R/GluN2B disruption with Tat-D2R-IL3
(intravenous):
• Inhibition of cocaine-induced decrease in
phospho-Ser1303 GluN2B.
• Acute hyperlocomotion & stereotypies
Liu et al. 2006
Mouse; cocaine (15mg/kg i.p) &
striatal cultures
D1R/GluN1 10 min after a co-stimulation of D1R and
NMDAR
D1R/GluN1 disruption with Tat-GluN1-C1 (infusion
into the NAcc):
• Blockade of striatal LTP.• Inhibition of cocaine-induced ERK1/2 activation.• Preservation of basal locomotion & acute
hyperlocomotor response to cocaine.
• Alteration of cocaine-mediated locomotor
sensitization induced by 2 injections.
Cahill et al., 2014b
Rat;
cocaine self-administration FR5
(0.5mg/kg per infusion i.v)
D2R/A2AR heteromers 2 hours after the last self-
administration session in the NAcc shell.
D2R/A2AR disruption with SynthTM5 (infusion in the
NAcc):
• Prevents the decrease in self-administration
induced by i.p. administration of CGS 21680.
Borroto-Escuela et al.,
2017a; 2018a
Rat;
amphetamine sensitization
(1.5mg/kg i.p)
Subchronic D2R/D1R disruption with Tat-D1 (i.c.v.
injection):
• Enhances locomotion• Prevents the decrease in sensitization induced by
s.c. administration of SKF83959.
Shen et al., 2015b
Rat;
cocaine locomotor sensitization
(10mg/kg i.p) ;
conditioned place preference (10
mg/kg i.p)
cocaine self-administration
(0.25 mg/infusion i.v)
Tat-D1 (i.c.v. injection) prevents the increase in D1R/
D2R co-immunoprecipitation induced by SKFss83959
D2R/D1R disruption with Tat-D1 (i.c.v. injection):
• Enhances the acute locomotor effect of cocaine as
well as sensitization.
• Induces conditioned place-preference• Enhances conditioned-place preference induced
by cocaine administration
• Enhances reinstatement of self-administration
response after extinction by a single cocaine
injection.
• Enhances delatFosB expression after repeated (7
days) injection.
• Prevents the conditioned place aversion induced
by administration of SKF83959
• Reverses the antagonistic effect of SKF83959 on
cocaine conditioned place preference
Perreault et al., 2016;
Hasbi et al., 2018
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functions (Wang et al., 2012; Cahill et al., 2014a). Instead, a selective
targeting of the molecular mechanisms responsible for the modulation
of excitatory transmission by DA appears as a promising strategy.
Beside local intracellular cascades downstream from DA receptors, a
growing body of evidence supports that the physical interaction be-
tween receptors is a powerful mechanism by which receptors can mu-
tually modify their functions through allosteric modulations. The for-
mation of such receptor oligomers can engage two, or more, identical
(homomers) or distinct (heteromers) receptors. These receptor com-
plexes have been the subject of intense investigation because they can
fine-tune downstream signaling and binding affinity of the component
receptors in a spatio-temporal manner, which makes them attractive for
the development of more selective pharmacological treatments for
numerous neurological and psychiatric diseases (Missale et al., 2006,
2013; Borroto-Escuela et al., 2017a, 2017b). DA receptors have been
shown – mostly in heterologous systems – to form many heteromers
with other GPCR, ionotropic channels and transmembrane proteins,
resulting in functional changes of partner receptors, modification of
binding affinity for ligands and biased signaling. The diversity and
biophysical properties of DA receptor heteromers have been ex-
haustively reviewed elsewhere (Wang et al., 2012; Ferré et al., 2016).
Moreover, numerous studies showed the critical role of the physical
interaction between DA receptors and NMDAR for their reciprocal
modulation (Lee et al., 2002; Pei et al., 2004; Cepeda and Levine, 2006;
Wang et al., 2012; Ladepeche et al., 2013), which makes them parti-
cularly relevant for drug addiction.
The current review focuses on reports that were able to provide
proof of concept that endogenous DA receptor heteromers in the brain
can be modulated in response to exposure to drugs of abuse and
eventually participate to drug-evoked neuronal adaptations (Table 1).
For each DA receptor heteromer, we start from its historical discovery
in heterologous systems, the identification of the protein-protein in-
teraction domains and associated changes in signaling, to finally discuss
their modulation in vivo and the strategies used to establish their po-
tential roles in drug-evoked adaptations.
2. D2R heteromers and addiction
Notably because alterations of D2R-mediated signaling have been
associated with numerous pathologies, there has been extensive work to
identify putative heteromers formed by the D2R. Most of them were
characterized in heterologous systems by bioluminescence or fluores-
cence resonance transfer (BRET/FRET) analyses, co-immunoprecipita-
tion, or indirectly through modulation of ligand binding affinity and
signaling effectors. These studies led to the identification of numerous
and diverse receptors that are able to form complexes with the D2R and
alter downstream signaling through allosteric modulations, as ex-
tensively reviewed (see Fuxe et al., 2014; Borroto-Escuela and Fuxe,
2017). Herein, we focus on D2R heteromers for which a functional
impact has been characterized in vivo.
2.1. D2R/A2AR heteromers
The purinergic system plays an antagonistic role onto DA trans-
mission, an effect mainly achieved through the adenosine A2A receptor
(A2AR), which expression is restricted to iMSN (Schiffman et al., 2007)
where it is highly colocalized with the D2R. As suggested by proximity-
ligation assay (PLA) on striatal tissue, a subset of A2AR and D2R are in
close proximity, which supports the existence of A2AR/D2R heteromers
in vivo (Trifilieff et al., 2011; Fernandez-Duenas et al., 2015; He et al.,
2016; Borroto-Escuela et al., 2017a, 2018a).
Historically, the work on interactions between striatal adenosine
and dopamine signaling began with the original observation that caf-
feine and theophyllamine, which antagonize adenosine receptors, were
able to enhance the antiparkinson actions of levodopa and DAR ago-
nists in a model of hemiparkinson rats (Fuxe and Ungerstedt, 1974).
Later on, the first indirect evidence for the existence of D2R/A2AR
heteromers came from the observation that the A2AR agonist CGS
21680 was able to decrease D2R affinity for the agonist apomorphine in
native membranes prepared from the rat striatum, suggesting allosteric
modulations within D2R/A2AR complexes (Ferré et al., 1991). Since
this discovery, extensive work, mainly by Ferré’s and Fuxe's groups,
characterized the biophysical and pharmacological properties of D2R/
A2AR heteromers, which have become a model study of allosteric
modulation between GPCR (Ferré et al., 2018; Borroto-Escuela et al.,
2018a). The extensive description of the biophysical properties of D2R/
A2AR heteromers is out of the scope of the current article but re-
markable recent reviews can be recommended (Ferré et al., 2016,
2018). A current model developed by Ferré and collaborators propose
that A2AR/A2AR and D2R/D2R homodimers, coupled to their re-
spective G protein – Gs/olf and Gi/o, constitute an heterotetrameric
structure forming a macromolecular complex with type 5 adenylate
cyclase (AC5) (Navarro et al., 2018; Ferré et al., 2018). Electrostatic
interactions between transmembrane domains (TM) 6 form the homo-
dimer interface, while heteromeric interactions involve TM 4 and 5 of
one receptor within each homodimer (see Navarro et al., 2018). D2R/
A2AR heteromerization results in negative allosteric interactions by
which A2AR ligands – agonists and antagonists - decrease the affinity
and efficacy of D2R ligands (Azdad et al., 2009; Bonaventura et al.,
2015) and, reciprocally, D2R agonists inhibit A2AR-dependent activa-
tion of AC5 (Navarro et al., 2018). In terms of signaling, this antag-
onistic interaction would result in a switch from cyclic AMP- to PLC-
and arrestin-dependent pathways, whether stimulation of A2AR or
D2R, respectively, is dominant (Borroto-Escuela et al., 2011; see Ferré
et al., 2018 for review).
These unique properties of D2R/A2AR heteromers have opened new
routes for pharmacological strategies for pathologies related to altera-
tions in DA transmission. For instance, even though the direct depen-
dence to D2R/A2AR heteromers has not been demonstrated, preclinical
evidence support some efficacy of A2AR antagonists to alleviate
symptoms in Parkinson's disease (Salamone et al., 2013; Podurgiel
et al., 2016) or apathy – i.e. loss of motivation (Mott et al., 2009;
Salamone et al., 2009; Pardo et al., 2012; Nunes et al., 2013; Randall
et al., 2014; Lopez-Cruz et al., 2018). Recently, Volkow and colleagues
showed that the psychostimulant caffeine, a potent A2AR antagonist,
enhances D2R availability in healthy control subjects measure by Po-
sitron Emission Tomography (PET) (Volkow et al., 2015). It is unclear
whether this effect results from upregulation of membrane expression
of D2R or change in their binding affinity for the radioligand (11C)-
Raclopride, but Ferré and colleagues proposed that it could directly
result from the “ability of caffeine to antagonize the effect of en-
dogenous adenosine on the binding of exogenous D2R antagonist”
(Ferré et al., 2018). This hypothesis remains to be tested but these
observations highlight the potential interest of D2R/A2AR hetero-
merization in the modulation of D2R activity and binding affinity. Yet,
a decrease in striatal D2R availability in subjects suffering from drug
addiction is one of the most consistent findings in PET imaging (Koob
and Volkow, 2016; Trifilieff et al., 2017). The causes for such decrease
are still unclear and could be both a consequence of drug exposure and/
or a vulnerability factor for drug abuse. Nevertheless, this neurobiolo-
gical feature is likely to constitute a central mechanism for the devel-
opment of addiction (Trifilieff and Martinez, 2014). Because the use of
selective D2R ligands would impact crucial physiological functions and
lead to severe unwanted side-effects, compounds that could act as al-
losteric modulators of D2R activity are a promising strategy in the field
of addiction. In this context, D2R/A2AR heteromerization should be
considered as a potential target.
Accordingly, preclinical data suggest that D2R/A2AR hetero-
merization could be involved in some aspects of addiction for psy-
chostimulants. Extended cocaine self-administration resulted in an in-
creased binding for (3H)-ZM 241385 – an A2AR antagonist – in the
NAcc of rats, which was reversed after extinction or withdrawal
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(Marcellino et al., 2007; Frankowska et al., 2013). Moreover, cocaine
self-administration increases D2R/A2AR complexes in the shell of the
NAcc (Borroto-Escuela et al., 2017a). The functional significance of this
increased D2R/A2AR heteromerization was assessed with an interfering
peptide corresponding to the TM5 of A2AR, which prevents D2R/A2AR
interaction in heterologous system. Local administration of this peptide
in the NAcc of rats the last 2 days of cocaine self-administration pre-
vented the decrease in self-administration induced by injection of the
A2AR agonist CGS 21680. Specificity of the TM5 interfering peptide
was verified by showing that administration of a peptide corresponding
to the TM2 of A2AR, which preserves D2R/A2AR interaction, had no
effect (Borroto-Escuela et al., 2018b). Further work is necessary to
characterize the impact of alterations of D2R/A2AR heteromers on
psychostimulants self-administration. However, the fact that this al-
losteric interaction results in an inhibition of D2R-dependent trans-
mission suggests that preventing the formation of D2R/A2AR hetero-
mers could be an efficient strategy to modulate D2R activity, which is
blunted in substance use disorders.
Of note, the D2R/A2AR interaction could also take place within
higher-order oligomers. As an example, complexes with metabotropic
glutamate type 5 receptors (mGluR5) have been detected by co-im-
munoprecipitation from striatal tissue (Cabello et al., 2009). Pharma-
cological experiments suggest that, within this receptor complex, A2AR
and mGluR receptors could act synergistically to inhibit D2R (Beggiato
et al., 2016). The D2R has also been shown to form higher-order het-
eromers with the sigma-1 receptor, which is able to directly bind co-
caine (Navarro et al., 2013; Beggiato et al., 2017). These complexes
have been detected in the striatum (Beggiato et al., 2017) but their
functional implication in cocaine-induced adaptations remain to be
demonstrated.
2.2. D2R/GluN2B heteromers
The integration of DA- and glutamate-dependent signaling within
the reward circuitry plays functional roles in drugs of abuse-evoked
long-lasting alterations (Lüscher and Malenka, 2011; Pascoli et al.,
2014a; Bellone and Gardoni, 2015). In addition to mGluR, glutamate
binds to ionotropic receptors of the α-amino-3-hydroxy-5-methyl-4-
isoxazole propionic acid (AMPAR), kainate and NMDA subtypes, which
mediate most of the excitatory neurotransmission in the brain and play
key roles in synaptic plasticity (Traynelis et al., 2010).
NMDAR are voltage-gated calcium (Ca2+) channels playing pivotal
roles in modulating synaptic transmission. Alterations of their functions
have been associated with numerous developmental, neurological and
psychiatric disorders, including addiction (Lau and Zukin, 2007).
NMDAR are heteromeric structures composed of two obligatory GluN1
subunits (formerly named NR1) and two regulatory GluN2 (GluN2A,
GluN2B, GluN2C, GluN2D) and/or GluN3 subunits (GluN3A, GluN3B).
Depending on the subunit composition, NMDAR fall into two main
categories, the di-heteromeric (GluN1 with identical GluN2) or the tri-
heteromeric ones, composed of GluN1 associated to a mixture of GluN2
and/or GluN3 subunits. Most differences between these subunits mainly
reside in their intracellular C-terminal domains (CTD), which are sub-
jected to post-translational modifications controlling NMDAR traf-
ficking, protein interactions, Ca2+ dynamics and coupling to specific
pathways (Paoletti et al., 2013). Among other post-translational mod-
ifications, Ca2+/calmodulin-dependent protein kinase II (CaMKII)
(Omkumar et al., 1996) and protein kinase C (PKC) (Liao et al., 2001)
can phosphorylate the GluN2B CTD on Ser1303, which enhances NMDA
currents (Lieberman and Mody, 1994; Liao et al., 2001), notably by
favoring NMDAR surface expression (Jin et al., 2015).
In an attempt to identify the molecular mechanisms underlying the
integration of DA and NMDA-mediated signals in response to drugs of
abuse, Liu and coworkers highlighted a direct physical interaction be-
tween D2R and GluN2B subunits in post synaptic density (PSD) frac-
tions of the rat hippocampus, prefrontal cortex and striatum (Liu et al.,
2006). They observed that a single cocaine injection triggers an in-
creased D2R/GluN2B heteromerization in the NAcc and dorsal
striatum, paralleled by a decrease of phospho-GluN2B-Ser1303. This was
strictly dependent on D2R signaling since the D2R antagonist Eticlo-
pride blocked both cocaine-mediated inhibition of phospho-GluN2B-
Ser1303 and D2R/GluN2B interaction, while a D2R agonist had opposite
effects. The protein domains involved in D2R/GluN2B interaction were
then characterized and the residues R220-A234 within third intracellular
loop of D2R (D2R-IL3) appeared as critical for the binding of D2R to the
CTD of GluN2B (Fig. 1a). By using a penetrating peptide corresponding
this R220-A234 -D2R-IL3 fragment, which disrupts D2R/GluN2B het-
eromers (Fig. 1b), it was shown that the cocaine-induced stimulation of
D2R facilitates the D2R/GluN2B interaction, leading to a decrease of
NMDAR currents in iMSN. This inhibition of NMDAR relies on a com-
petition mechanism whereby D2R/GluN2B heteromers induced by co-
caine disrupt the binding of CaMKII to GluN2B and reduces CaMKII
activity (Fig. 1c). At the behavioral level, disruption of D2R/GluN2B
interaction inhibits the acute hyperlocomotion and stereotypies in-
duced by a single high dose of cocaine (Liu et al., 2006). This pioneer
study strongly supports the hypothesis that D2R/GluN2B heteromers
Fig. 1. Formation, regulation and func-
tions of heteromers formed dopamine
and NMDA receptors in response to drugs
of abuse. (a) Diagram depicting the for-
mation of D2R/GluN2B-NMDAR heteromers
through the interaction of a fragment of the
D2R-IL3 with the CTD of GluN2B. (b) Mode
of action of the cell-permeable Tat-D2R-IL3
peptide, which disrupt D2R/GluN2B inter-
action. (c) A single cocaine administration
favors D2R/GluN2B heteromerization in the
striatum. Consequently, the binding of
CaMKII to GluN2B is altered, which de-
creases GluN2B phosphorylation of Ser1303
and inhibits NMDAR functions in D2R-MSN
(see Liu et al., 2006). (d) In D1R-MSN, sti-
mulation of D1R triggers a D1R-dependent,
and Fyn-mediated, phosphorylation of
GluN2B on Tyr1472, which triggers a down-
stream Ca2+-dependent activation of ERK1/
2 controlling cocaine-induced long-term adaptations (see Pascoli et al., 2011a, 2014a). Schematic representation of D1R/GluN1 (e) and D1R/Glu2A (f) hetero-
merization. (g) The disruption of D1R/GluN1 heteromers with the Tat-GluN1-C1 blocks the facilitation of Glu2NB-NMDAR by D1R and downstream ERK activation
and striatal LTP in dMSN, while preserving the function of individual D1R and NMDAR (see Cahill et al., 2014b).
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could mediate the inhibitory effects of psychostimulants on iMSNs.
However, it raises several important questions that we are currently
pursuing. With regard to the chronic nature of addiction-related dis-
orders, it would be important to determine how D2R/GluN2B hetero-
mers are modulated in response to repeated exposure cocaine and if
disrupting D2R/GluN2B interaction could overcome cocaine-evoked
long-lasting responses. Furthermore, the R220-A234 -D2R-IL3 peptide
used to alter D2R/GluN2B interaction comprises a part of the Arginine-
rich domain of D2R that is critical for its binding to A2AR (Ciruela
et al., 2004; see section 2.1). Using a shorter D2R-IL3 peptide that se-
lectively alters D2R/GluN2B interaction would definitely precise the
specific role of D2R/GluN2B in long-term effects of drugs of abuse. This
is particularly relevant in light of recent evidence showing that D2R-
mediated inhibition of NMDAR also involves D2R/A2AR interaction
(Azdad et al., 2009).
2.3. D1R/D2R heteromers
Another DA receptor heteromer that has been extensively studied,
mostly by the group of Susan R. George, is the one formed by the D1R
and D2R. Co-expression of both receptors in the striatum has been re-
ported mostly in the shell of the NAcc (Deng et al., 2006; Hasbi et al.,
2009; Perreault et al., 2010; Gangarossa et al., 2013; Frederick et al.,
2015; Gagnon et al., 2017) and D1R/D2R complexes were detected by
PLA in situ in the striatum of rodents and non-human primates
(Perreault et al., 2016; Rico et al., 2017; Hasbi et al., 2018), even
though there has been some controversy since the work form Frederick
and co-workers showed D1R/D2R complexes were not detectable by
using the same approach in vivo in mice within the fraction of MSN
expressing both D1R and D2R receptors (Frederick et al., 2015). In
heterologous systems, the formation of D1R/D2R complexes could lead
to atypical signaling: instead of the canonical Gs/olf and Gi/o proteins,
D1R/D2R heteromers would be able to recruit Gq protein, leading to
PLC-mediated intracellular Ca2+ release (Perreault et al., 2014). It was
argued that the D1R ligand SKF83959 preferentially recruits D1R/D2R
heteromer-dependent Ca2+ signaling, due to alterations of the D1R
binding pocket when in the heteromeric complex, supporting the idea
of an allosteric modulation within the D1R/D2R heteromers (Hasbi
et al., 2009, 2010; Verma et al., 2010; Perreault et al., 2014).
To target D1R/D2R heteromers, Hasbi et al. (2014) designed and
interfering peptide, based on putative interaction sites between both
receptors involving 2 adjacent Arginine in the D2R-IL3 and 2 adjacent
Glutamic acid of the D1R CTD (O'Dowd et al., 2012). This “Tat-D1”
peptide, corresponding to amino acid 396–413 of the D1R CTD, was
shown to perturb i) D1R/D2R – but not D2R-D5R - interaction, ii)
SKF83959-induced Ca2+ transients in vitro and iii) co-im-
munoprecipitation from membrane extracts, while a scrambled peptide
had no effect (Hasbi et al., 2014).
In the context of addiction, the Tat-D1 peptide was shown to reverse
the SKF83959-induced inhibition of amphetamine sensitization (Shen
et al., 2015a). The same group showed that the Tat-D1 peptide alone
enhanced cocaine-induced locomotor sensitization and place-pre-
ference, as well as the reinstatement after self-administration (Perreault
et al., 2016; Hasbi et al., 2018). It should be noted that the Tat-D1
peptide displayed, by itself, pro-locomotor effects (Shen et al., 2015a)
and induced place-preference (Perreault et al., 2016; Hasbi et al.,
2018). Importantly, the Tat-D1 peptide used to disrupt D1R/D2R in-
teraction strongly overlaps with the so-called “Tat-D1R-t2 peptide”
originally designed to block D1R/NMDAR heteromers (Nai et al., 2010;
Ladepeche et al., 2013; see section 3.1). Furthermore, the Tat-D1R-t2
was shown to induce, by itself, ERK activation (Cahill et al., 2014b) and
to potentiate glutamatergic synapses (Ladepeche et al., 2013), sug-
gesting that this peptide could mimic D1R/NMDA interaction (see
section 3.1), which could explain the pro-rewarding effect of the Tat-D1
peptide used by the George's group. The specificity of the Tat-D1 pep-
tide in selectively impairing D1R/D2R interaction has therefore to be
further validated. Moreover, most of the in vivo effects of the Tat-D1
peptide were assessed through its ability to abolish/attenuate the be-
havioral impact of SKF83959 (Hasbi et al., 2014, 2018; Shen et al.,
2015a,b). Yet, the properties of SKF83959 as a preferential ligand for
D1R/D2R heteromers capable of recruiting Gq-dependent mechanisms
has been recently challenged (Chun et al., 2013; Lee et al., 2014a,b;
Frederick et al., 2015). Further work is needed to unravel the unique
properties of this atypical subpopulation of MSN co-expressing both
D1R and D2R and their potential regulation by putative D1R/D2R
heteromers.
3. D1R heteromers and addiction
3.1. D1R/NMDA heteromers
As opposed to the inhibitory role of D2R on NMDAR currents (see
section 2.3), there is a general consensus toward a facilitating effect of
D1R stimulation on NMDAR functions (Flores-Hernandez et al., 2002;
Wittmann et al., 2005; but see Lee et al., 2002). This positive feedback
is bi-directional since NMDAR stimulation also favors D1R surface ex-
pression and downstream cAMP production (Pei et al., 2004). The
mechanisms underlying the interplay between D1R and NMDAR signals
have been intensely investigated, notably because targeting these pro-
cesses offers the prospect of restoring the imbalance in D1R and
NMDAR functions described in numerous psychiatric diseases (Cepeda
and Levine, 2006; Missale et al., 2006; Yao et al., 2008; Wang et al.,
2012).
The synergy between D1R and NMDAR plays functional roles in
drug of abuse-mediated responses. We observed that psychostimulant-
mediated striatal activation of ERK1/2, which controls long-term neu-
ronal adaptations, relied on a concomitant stimulation of D1R and
NMDAR (Valjent et al., 2000, 2005; Pascoli et al., 2011a). This con-
vergence of DA and glutamate signals onto ERK1/2 involves a D1R-
mediated phosphorylation of GluN2B-containing NMDAR on Tyr1472
via the tyrosine kinase Fyn, which triggers a Ca2+-dependent activation
of ERK1/2 that launches cocaine-induced epigenetic, genic, morpho-
logical and behavioral changes (Fig. 1d; Pascoli et al., 2011a). In ad-
dition to signaling cascades linking D1R stimulation to a facilitation of
GluN2B-NMDAR, the potential role D1R/NMDAR heteromers in drug of
abuse-evoked plasticity is only emerging.
The seminal work of Fang Liu and colleagues led to the identifica-
tion of a direct binding of D1R, but not D5R, to the GluN1 and GluN2A
subunits of NMDAR in cultured cells overexpressing the receptors, and
hippocampal tissues (Lee et al., 2002; Pei et al., 2004). These D1R/
GluN1 complexes were also detected in the mouse striatum (Cahill
et al., 2014b), including in PSD fractions (Fiorentini et al., 2003), as
well as in human post-mortem caudate putamen tissues (AA, ESJ, RW,
PT, PV unpublished observations). In vitro assays showed that the D1R-
t2 (L387- L416) and D1R-t3 (S417-T446) domains of D1R CTD bind to the
CTD of GluN1 and GluN2 subunits, respectively (Fig. 1e–f; Lee et al.,
2002). The D1R-t2 domain binds to the C1 cassette of GluN1 (GluN1-
C1; D864- T900; Lee et al., 2002; Fiorentini et al., 2003; Pei et al., 2004),
which comprises multiple PKA and PKC phosphorylation sites (Tingley
et al., 1997; Wang et al., 2014) and controls NMDAR trafficking (Ehlers
et al., 1995; Scott et al., 2003). Pull-down assays coupled to mass
spectrometry established that electrostatic interactions between the
Arginine-rich epitope localized in GluN1-C1 and the acidic residues in
the D1R-t2 region mediate D1R/GluN1 interaction (Woods et al.,
2005). These findings highlight the importance of epitope-epitope
electrostatic interactions for both D1R/NMDA and D2R/A2AR (see
section 2.1), suggesting that they might represent a general mechanism
for receptor heteromerization. Of note, the D1R-t2 and GluN1-C1 amino
acid sequences are conserved across species, supporting the hypothesis
that D1R/NMDAR heteromers might be involved in physiological
functions that have been preserved through evolution (Woods et al.,
2005).
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Studies on the modulation of D1R/GluN1 interaction by receptor
agonists or antagonists led to controversial findings, with authors re-
porting a D1R agonist-dependent decrease of endogenous D1R/GluN1
heteromers in cultured hippocampal neurons (Lee et al., 2002), whereas
BRET experiments performed on cell lines overexpressing the receptors
showed no effect of D1R or NMDAR agonists and antagonists
(Fiorentini et al., 2003).
To study whether cocaine could modulate endogenous D1R/GluN1
heteromerization, we first used cultured striatal neurons co-stimulated
with a D1R agonist together with a low dose of glutamate, a model that
we validated as instrumental to study cocaine-evoked signaling in vivo
(Pascoli et al., 2011a; Cahill et al., 2014b). Notably, this co-stimulation
paradigm, which induces a D1R-mediated facilitation of NMDAR as
observed in vivo in response to cocaine, led to a significant increase of
D1R/GluN1 heteromers (Cahill et al., 2014b). Their potential role in the
convergence of D1R and NMDAR signals onto ERK1/2 activity was
assessed with a cell-penetrating peptide corresponding to the C1 cas-
sette of GluN1 (TAT-GluN1-C1; Fig. 1g). This peptide efficiently dis-
rupted D1R/GluN1 heteromerization induced by the co-stimulation, as
well as the D1R-mediated potentiation of Ca2+ transients through
GluN2B-NMDAR and downstream ERK activation. Importantly, the
TAT-GluN-C1 peptide was able to block the D1R/NMDAR-dependent
signaling, while preserving the functions of individual D1R and NMDAR
(Cahill et al., 2014b). The inhibition of D1R/GluN2A interaction with a
TAT-D1R-t3 peptide had no effect on ERK1/2 activation downstream of
D1R and NMDAR. These observations posit D1R/GluN1 heteromers as
the molecular bridge linking DA to the facilitation of NMDAR and ERK
activation in an in vitro model of cocaine exposure.
Since drug-induced adaptive behavior has been causally linked to
long-term synaptic plasticity of glutamate synapses onto dMSN (Pascoli
et al., 2011b, 2014b), it seems critical to determine whether D1R/
NMDAR heteromers are present at synaptic sites and can control sy-
naptic plasticity.
On organotypic striatal cultures the lateral diffusion of D1R at the
plasma membrane is greatly reduced upon NMDAR stimulation, which
favors confined D1R expression within dendritic spines. This recruit-
ment of D1R in spines depends on D1R/GluN1 heteromer formation,
leading to the model of ‘diffusion trap system” whereby agonist-in-
duced allosteric changes of NMDAR enhances D1R/NMDAR interaction
at synaptic sites (Scott et al., 2006). This model stipulates that upon
glutamate release, D1R/NMDAR heteromers are preferentially formed
within, or at the close vicinity of, synapses. Accordingly, the CTD of
both GluN2 subunits of NMDAR and D1R are known to bind the sy-
naptic protein PSD-95, which stabilizes their localization at synapses
(Kornau et al., 1995; Niethammer et al., 1996; Kim and Sheng, 2004;
Zhang et al., 2009; Ladepeche et al., 2013). The expression of both
receptors is thus confined at synaptic sites owing to their interaction
with PSD-95. However, Zhang and colleagues demonstrated that GluN1
and PSD-95 bind to the D1R CTD through docking sites that overlap at
the level of the D1R-t2 domain (Zhang et al., 2009). Through a com-
petition mechanism, PSD-95 is thus a limiting factor for D1R/GluN1
heteromerization at synapses, even though these receptors complexes
are detected in striatal PSD fractions (Fiorentini et al., 2003).
To assess the role of D1R/GluN1 interaction in the modulation of
synaptic transmission, electrophysiological recordings were performed
from cortico-striatal slices prepared from the drd1a-egfp reporter mice
to visualize dMSN (Gong et al., 2003). Inhibition of D1R/NMDAR in-
teraction with the GluN1-C1 peptide fully blocked D1R-mediated fa-
cilitation of NMDA-mediated excitatory post-synaptic currents, while
sparing basal synaptic transmission (Cahill et al., 2014b). A GluN2B
antagonist was also able to abrogate the D1R-mediated facilitation of
NMDA currents, whereas disruption of D1R/GluN2A heteromers with
the D1R-t3 peptide had no effect. This suggests that D1R/GluN2A
heteromers are not primarily involved in the modulation of NMDAR
currents by DA in dMSN. It also shows that D1R/GluN1 interaction
preferentially modulates GluN2B-NMDAR, even though the underlying
mechanism is still unknown.
To study the role of D1R/GluN1 interaction in striatal plasticity,
high frequency electrical stimulations (HFS) of the cortex triggering
long-term potentiation (LTP) of striatal synapses in both dMSN and
iMSN were applied to cortico-striatal slices (Pascoli et al., 2011b). This
allowed us to demonstrate the mandatory role of D1R/NMDAR het-
eromers for LTP in dMSN, but not iMSN (Cahill et al., 2014b). Ac-
cordingly, the facilitating effect of D1R on NMDAR-mediated LTP also
required D1/NMDAR interaction in the hippocampus (Nai et al., 2010).
In contrast, Ladepeche and co-workers found that blocking D1R/GluN1
interaction with the TAT-D1R-t2 peptide increased the number of po-
tentiated synapses in a chemically-induced LTP in cultured hippo-
campal neurons (Ladepeche et al., 2013). The apparent discrepancy
between these results is likely due to differences in experimental
models (cortico-striatal slices v.s hippocampal neurons) and/or to the
strategies used to block D1R/GluN1 heteromers. In fact, we found that
the D1R-t2 peptide was able to activate NMDAR and ERK by itself
(Cahill et al., 2014b), which could explain its permissive effect on
chemical LTP. By contrast, when using the GluN1-C1 peptide, which
disrupts D1R binding to NMDAR without affecting the functions of in-
dividual D1R and NMDAR, we observed a blockade of HFS-induced
striatal LTP (see Andrianarivelo et al., 2018). Regarding cocaine-evoked
responses in vivo, the infusion of the TAT-GluN1-C1 peptide into the
NAcc was able to attenuate cocaine-induced ERK1/2 activation. In-
hibiting D1R/GluN1heteromers in the NAcc did not impact neither the
basal locomotion nor the acute hyperlocomotor response to a first in-
jection. By contrast, the disruption of D1R/GluN1 interaction prior and
during the first injection of cocaine altered the locomotor sensitization
induced by a second injection of cocaine administered a week later
(Cahill et al., 2014b). This supports a role for D1R/GluN1 heteromers in
the NAcc in the development of persistent cocaine-induced adaptations
in acute models of cocaine exposure. To date, the impact of acute or
chronic exposure on endogenous D1R/GluN1 heteromerization in vivo
in the striatum and in other brain structures of the reward circuit is still
not known. Whether or not these heteromers are involved in the de-
velopment and maintenance of long-lasting structural and behavioral
adaptation remains to be established. We are currently tackling these
issues, which are critical because they will unravel whether of D1R/
GluN1 and D2R/GluN2 heteromers are mediators of the excitatory and
inhibitory actions of drugs of abuse on dMSN and iMSN, respectively.
4. Conclusions and perspectives
Numerous studies focused on the mechanisms underlying allosteric
changes induced receptor heteromerization and associated modification
of downstream signaling but only few reports described roles of en-
dogenous heteromers in vivo (Table 1). This is likely due to limitations
of current approaches to detect heteromers in situ. In fact, class C GPCRs
form stable oligomers but class A GPCRs oligomerization seems highly
dynamic, and its existence is still a matter of debate. Furthermore, most
discoveries on receptor oligomers originate from studies in hetero-
logous systems lacking the dense synaptic macroproteic complexes
where receptors have multiple and dynamic interactors. These inter-
actions, sometimes involving overlapping sites, represent a major
challenge to selectively alter heteromer formation without impacting
on the component receptor's interaction with other partners. This im-
plies a thorough characterization of potential off-target effects and
caution when interpreting the results. Such strategy design could ben-
efit from crystal structures of the receptors to model the interface of
heteromers, as recently performed for D2R/A2R (Borroto-Escuela et al.,
2018c). This could facilitate the identification of the minimal amino-
acid residues necessary for receptor heteromerization, the design of
non-peptidic interfering molecules or bi-valent compounds selectively
targeting receptor oligomers (Soriano et al., 2009).
Several DA receptors heteromers with a therapeutic potential have
been described, including D1R/D3R (Fiorentini et al., 2010), but their
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roles remain to be established. Moreover, most studies on receptor
heteromers in addiction focused on the striatum because of its key role
in the pathology and its enrichment in DA receptors. However, a
thorough characterization of heteromer expression within the entire
brain reward circuit would be of importance considering the implica-
tion of various brain regions in distinct components of addiction.
Moreover, the implication of DA receptor heteromers has been mainly
studied in the initial phases of drug exposure. Addressing their roles in
each phases of drug addiction (maintenance, craving and relapse)
seems of crucial importance as it could open new routes for the de-
velopment of selective strategies targeting these heteromers for the
treatment of drug addiction.
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